

Creo Medical Group plc

Significant Shareholders as at 31 December 2023¹

Name of shareholder	Number of shares	Voting rights (%)
Canaccord Genuity ²	46,982,275	13.01
M&G Investments	33,612,732	9.30
Baillie Gifford	23,421,836	6.48
Finance Wales Investments	19,776,727	5.47
Amati Global Investors	16,998,915	4.71
AXA Framlington Investment Managers	16,081,958	4.45
Hargreaves Lansdown, stockbrokers (EO)	15,639,270	4.33
River Global Investors	14,375,697	3.98

Director Shareholdings (excluding options) as at 31 December 2023

Director	Number of shares	Voting rights (%)
Charles Spicer	308,530	0.09
John Bradshaw	1,371,082	0.38
Ivonne Cantu	125,000	0.03
Craig Gulliford ³	1,638,320	0.45
Mr Richard Rees	2,813,756	0.78
Prof. Christopher Hancock	4,810,206	1.33
David Woods	440,255	0.12
Total	11,507,149	3.18

Percentage of AIM Securities not in public hands as at 31 December 2023: 21.73%

¹ Information obtained from an analysis of Creo Medical's share register (dated 31 December 2023) undertaken on behalf of Creo Medical by Equiniti - RD:ID.

² Canaccord Genuity Wealth Management (Inst) - 42,647,141- 11.81%; Canaccord Genuity Wealth Management (ND) - 4,335,134 - 1.20%.

³ Includes 1,000,000 shares held by Craig Gulliford's wife.